克唑替尼治疗c-MET扩增阳性肺腺癌胸膜转移患者1例并文献复习

被引：1

作者：

郑瑶 ^{[1
,2
]}

胡玉琴 ^{[2
]}

姚俊涛 ^{[2
]}

赵征 ^{[2
]}

机构：

[1] 西安医学院

[2] 西安交通大学医学院附属陕西省肿瘤医院

来源：

现代肿瘤医学 | 2018年 / 26卷 / 22期

关键词：

克唑替尼; c-MET扩增; 肺腺癌;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

目的:探讨肝细胞生长因子受体(cellular-mesenchymal to epithelial transition factor,c-MET)阳性的非小细胞肺癌(non-small cell lung cancer,NSCLC)胸膜转移患者的临床特征、诊断及治疗。方法:采用二代测序技术NGS检测1例患者c-MET基因为扩增阳性,在一线化疗失败后,给予克唑替尼(crizotinib)治疗,250 mg,2次/日。并对该病例资料进行复习,随访至2017年7月病人死亡。结果:该患者服用克唑替尼4周后,总体疗效评价为部分缓解(partial response,PR)。结论:c-MET扩增阳性伴胸膜转移的肺腺癌患者服用克唑替尼治疗可获益。

引用

页码：3593 / 3597

页数：5

共 15 条

[1]

HGF/c-MET抑制剂治疗非小细胞肺癌的研究进展 [J].

蒋涛 ;

周彩存 .

中国肺癌杂志, 2015, (04) :240-244

[2]

驱动基因指导下的晚期非小细胞肺癌靶向治疗 [D].

张童童 .

北京协和医学院,

2017

[3]

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation [J].

Jorge, Susan E. ;

Schulman, Sol ;

Freed, Jason A. ;

VanderLaan, Paul A. ;

Rangachari, Deepa ;

Kobayashi, Susumu S. ;

Huberman, Mark S. ;

Costa, Daniel B. .

LUNG CANCER, 2015, 90 (03) :369-374

[4]

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation [J].

Jenkins, Russell W. ;

Oxnard, Geoffrey R. ;

Elkin, Sheryl ;

Sullivan, E. Kelly ;

Carter, Jennifer L. ;

Barbie, David A. .

CLINICAL LUNG CANCER, 2015, 16 (05) :E101-E104

[5]

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping [J].

Paik, Paul K. ;

Drilon, Alexander ;

Fan, Pang-Dian ;

Yu, Helena ;

Rekhtman, Natasha ;

Ginsberg, Michelle S. ;

Borsu, Laetitia ;

Schultz, Nikolaus ;

Berger, Michael F. ;

Rudin, Charles M. ;

Ladanyi, Marc .

CANCER DISCOVERY, 2015, 5 (08) :842-849

[6]

MET Mutation Associated with Responsiveness to Crizotinib [J].

Waqar, Saiama N. ;

Morgensztern, Daniel ;

Sehn, Jennifer .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (05) :E29-E31

[7]

MET-Mutated NSCLC with Major Response to Crizotinib [J].

Mendenhall, Melody A. ;

Goldman, Jonathan W. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (05) :E33-E34

[8]

Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer.[J].Alice T. Shaw;Sai-Hong I. Ou;Yung-Jue Bang;D. Ross Camidge;Benjamin J. Solomon;Ravi Salgia;Gregory J. Riely;Marileila Varella-Garcia;Geoffrey I. Shapiro;Daniel B. Costa;Robert C. Doebele;Long Phi Le;Zongli Zheng;Weiwei Tan;Patricia Stephenson;S. Martin Shreeve;Lesley M. Tye;James G. Christensen;Keith D. Wilner;Jeffrey W. Clark;A. John Iafrate.The New England Journal of Medicine.2014, 21

[9]

FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements [J].

Kazandjian, Dickran ;

Blumenthal, Gideon M. ;

Chen, Huan-Yu ;

He, Kun ;

Patel, Mona ;

Justice, Robert ;

Keegan, Patricia ;

Pazdur, Richard .

ONCOLOGIST, 2014, 19 (10) :E5-E11

[10]

Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) [J].

Camidge, D. Ross ;

Ou, Sai-Hong Ignatius ;

Shapiro, Geoffrey ;

Otterson, Gregory Alan ;

Villaruz, Liza Cosca ;

Villalona-Calero, Miguel Angel ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Dacic, Sanja ;

Cardarella, Stephanie ;

Zhao, Weiqiang ;

Tye, Lesley ;

Stephenson, Patricia ;

Wilner, Keith D. ;

James, Leonard Philip ;

Socinski, Mark A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 →